On the face of it, what was interesting for me:
- "losses" (when excluding Research and development expenses and Equity accounted loss of joint venture entity) increased slightly from $204k to $564k
- gross profit up almost 12%, with margins reasonably strong (not showing singes of dramatic decreases in gross margin to try sell more!)
- Australia is doing very well (and probably continue to grow in double digits)
- Rest of world will probably continue to treble in sales for the next few years
- NZ is performing "solidly" but will probably continue at mid single digits due to saturation (great to see market share is growing!)
Look forward to hearing what others are thinking, but this looks to be a keeper!
The big question is just how much dosh they are churning through with the research,and whether they are coming up with anything--I wonder if they would not be better off just promoting their established product(but whats the difference between just taking 1/2 tab of ibuprofen and 1/2 of paracetimal (i did the spell check on the misspelling of para and it told me ''malpractice'' --you gotta laugh sometimes)
Theres probably a big difference but Ive often wondered
Taking paracetamol and ibuprofen together is effectively the same, and a lot of doctors do actually prescribe this for post-operative pain relief (particularly with the current push to get away from opiate-based analgesics). However, in theory it's best for patient safety and compliance to simplify a prescription as much as possible (one tablet is better than two). As far as over-the-counter use is concerned, I imagine that users who find that a combination is best for their particular pain would also prefer to have a packet of the all-in-one tablet, plus it's safer if the combination dose is pre-measured instead of having a situation where consumers have to mix and match.
What I'm most interested in is whether they have a US sales partner lined up and what sort of marketing effort will be directed toward US healthcare providers.
Taking paracetamol and ibuprofen together is effectively the same, and a lot of doctors do actually prescribe this for post-operative pain relief (particularly with the current push to get away from opiate-based analgesics). However, in theory it's best for patient safety and compliance to simplify a prescription as much as possible (one tablet is better than two). As far as over-the-counter use is concerned, I imagine that users who find that a combination is best for their particular pain would also prefer to have a packet of the all-in-one tablet, plus it's safer if the combination dose is pre-measured instead of having a situation where consumers have to mix and match.
What I'm most interested in is whether they have a US sales partner lined up and what sort of marketing effort will be directed toward US healthcare providers.
Thats the million dollar question--IMO thats where PEB has stumbled...no big US partner
Fantastic annoucement! What is hard to believe is how the share price has 'barely' budged, given, what I think we can all agree on, is a very impressive annoucement... (I suppose the given the broader market weakness, where the nzx 50 is down 1.2% or so, getting any bump is 'ok')
Disclosure: very comformtable holder, just don't own enough
I've always been surprised at what a low EBITA they have when Maxigesic is so $$$ at the pharmacy and its active compounds are one of the most commoditised in the drug market.
The chart below is from an update dated Sept 12th - nice looking chart with the note that FY17 projection is based on 33 million tabs for first 5 months of year (heaps more than all of FY16
Even t_j was moved to say 'fantastic announcement' - even piqued my interest
But then H1 revenues are only going to be up 1%
Doesn't seem to make much sense
Please t_j - what the heck is going on here
Last edited by winner69; 17-11-2016 at 09:13 PM.
”When investors are euphoric, they are incapable of recognising euphoria itself “
Bookmarks